Journal of Pharmacokinetics and Biopharmaceutics, Vol. 24, No. 6, 1996

Author Index to Volume 24

Avram, M. J., 569

Barbhaiya, Rashmi H., 313
Bass, Ludvik, 19
Bates, Ronald A., 283
Bennett, J. E., 403
Blaschke, Terrence F., 265
Boer, Fred, 197
Bovill, James G., 197
Bruno, René, 153
Burm, Antoin G. L., 197

Calvert, A. Hilary, 313
Chappell, Michael J., 283
Chen, Fan, 491
Cheng, Haiyung, 389
Chiou, Win L., 433

De Phillips, Susan L., 153

Ette, Ene I., 637

Gillespie, William R., 389
Girard, Pascal, 265
Godfrey, Keith R., 283
Grant, Cliff, 1
Gray, Elke C., 1
Guengerich, F. Peter, 521

Hak, Adrie, 197
Hansel, Steven B., 219
Heinzl, Harald, 651
Henthorn, T. K., 569
Hoeft, Andreas, 197
Homer, Louis D., 589
Hovorka, Roman, 283

Iga, Tatsuji, 327
Igwemezie, Linus N., 313

Jacquez, John A., 301, 569
Jonsson, E. Niclas, 245
Jusko, William J., 611

Karlsson, Mats O., 245
Kastrissios, Helen, 265
Kaul, Sanjeev, 313
Keiding, Susanne, 19
Krejcie, T. C., 569
Kugler, Alan R., 349

Lee, Myung G., 551
Lee, Sun H., 551
Ludbrook, Guy L., 1
Ludden, Thomas M., 637

Madden, Francis N., 283
McLachlan, Andrew, 369
Meijer, Dirk K. F., 45
Meyer, Urs A., 449
Montay, Guy, 153
Morris, Marilyn, 219
Mummaneni, Vanaja, 313

Newell, David R., 313
Niemann, C. U., 569
Nilsson, Anders, 535

Olson, Stephen C., 349
Ott, Peter, 19
Owens, Ida S., 491

Parivar, Kourosh, 535
Porter, David, 313

0090-466X/96/1200-0663$09.50/0 © 1996 Plenum Publishing Corporation

Proost, Johannes H., 45
Purves, R. D., 79

Ring, Barbara J., 461
Ritter, Joseph K., 491
Roberts, Michael S., 173
Rowland, Malcolm, 369

Sawada, Yasufumi, 327
Schall, Robert, 133
Scholz, Martin, 197
Shanks, C. A., 569
Sharma, Amarnath, 611
Sheiner, Lewis B., 153, 265
Smith, David E., 349
Spielberg, Stephen P., 509
Staschen, Carl-Michael, 589
Sun, He, 637

Thomas, Huw, 313

Upton, Richard N., 1

VandenBranden, Mark, 461
Vergniol, Jean Claude, 153
Vivier, Nicole, 153

Wade, Janet R., 245
Wakefield, Jon C., 103, 403
Weiss, Michael, 173
Wessén, Arne, 535
Widman, Marianne, 535
Wierda, Mark K. H., 45
Wilkinson, Grant R., 475
Williams, Roger L., 133
Winograd, Benjamin, 313
Wrighton, Steven A., 461

Yamamoto, Koujirou, 327
Yeatman, Matthew T., 491

Journal of Pharmacokinetics and Biopharmaceutics, Vol. 24, No. 6, 1996

Subject Index to Volume 24

Absorption, 433, 551
Absorptive clearance, 433
Alfentanil, 197, 569
Allosteric model, 589
Anaesthesia, 535
Antibodies, 521
Antipyrine, 569
Azosemide, 551

Bayesian individualization, 103
Bilirubin UDP-glucuronosyltransferases, 491
Bioequivalence, 313
Bootstrap, 133
Brain, 1

Cancer, 313
Cerebral blood flow, 1
Cholinesterase inhibitor, 327
Compliance, 265
Conjugation/deconjugation, 219
Constrained optimization, 283
Context sensitive time, 535
Convolution analysis, 197
Cubic splines, 283
Cyclosporine, 475
CYP3A metabolism, 475
Cytochrome P450, 449, 461, 475, 521

Deconvolution, 283
Destructive sampling, 649
Diffusional barrier, 219
Distribution kinetics, 173
Docetaxel, 153
Dogs, 569
Drug delivery, 369
Drug interactions, 475
Drug metabolism, 449, 461, 521
Drug targeting index, 369
Drug transport, 433

Effect compartment model, 45
Eltanolone, 535
Enzyme distribution, 219
Enzymology, 521
Equilibrium, 589
Etoposide, 313
Etoposide phosphate, 313
Experimental design, 589

Flux of bound drug, 369
Fourier transforms, 283
Futile cycling, 219

Genetic algorithms, 283
Genetic defects, 491
Genetic locus, 491
Genetic polymorphism, 449
Glutathione *S*-transferase, 521

Healthy volunteers, 535
Hepatic removal, 19, 461
Humans, 197, 313, 461
Hydroxylamine metabolites, 509

Identifiability, 301
in vitro methods, 521
in vitro models, 461
in vitro prediction, 449
in vitro-in vivo relationship, 327
Indirect response models, 611
Individual bioequivalence, 133
Indocyanine green, 19, 197, 569
Induction, 449
Inhibitors, 521

0090-466X/96/1200-0665$09.50/0 © 1996 Plenum Publishing Corporation

Interindividual variation, 449
Intestinal absorption, 433
Isolated perfused hindlimb, 173
Isolated perfused rat kidney, 349

Kabi 2213, 535

Least squares, 79
Lidocaine, 173
Liver function test, 19
Lung metabolism, 197

Markov chain model, 265
Maximum entropy, 283
Mean residence time, 389
MEMS, 265
Metabolism, 349
Mixed effects models, 403
Model building, 153
Model validation, 153
Moment-based criteria, 133
Multiple indicator dilution, 173
Multiple peaks, 551

N-acetyltransferases, 509
NAT1, 509
NAT2, 509
Neuromuscular blocking agents, 45
Non-equilibrium, 589
Nonlinear protein binding, 389
Nonlinear regression analysis, 589
NONMEM, 153, 245, 403

Onset time, 45
Organic anions, 19, 349
Organic cations, 349

p-Nitrophenol, 219
Parameter estimation, 79, 403, 635
Permeability, 369, 433
Pharmacodynamic modeling, 45
Pharmacodynamics, 1, 313, 327, 551, 611
Pharmacokinetic modeling, 45
Pharmacokinetic tissue distribution, 197
Pharmacokinetics, 1, 79, 313, 535, 551
Physiologic models, 569
Physiologically based pharmacokinetics 19, 173
Pigs, 197
Pooled data methods, 301
POPKAN, 403
Population analysis, 245
Population bioequivalence, 133
Population pharmacokinetics, 103, 153, 265, 403, 635
Potency, 45
PPHARM, 403
Predictive distribution, 103
Pregnanolone, 535
Probability-based criteria, 133
Protein binding, 19, 45
Pulmonary capillary blood volume, 569
Pulmonary capillary transit time, 569
Pulmonary uptake, 569

Quinapril, 349
Quinaprilat, 349

Radioligand binding, 589
Receptor onset/offset rate, 45
Recombinant DNA technology, 521
Repeated measures data, 635
Reversible conjugation, 219

Sampling design, 245
Sampling time error, 635
Scaled criteria, 133
Selective advantage, 369
Simulation, 403
Stochastic model, 173
Study design, 245
Sufentanil, 197
Sulfonamide hypersensitivity reactions, 509
System identification, 283

Taxotere, 153
Terfenadine, 475
Therapeutic drugs, 491
Thiopentone, 1
Tissue binding, 45
Tissue diffusion, 173
Tissue distribution, 569
Transit time distribution, 173
Transport, 349
Transport resistance, 433
Two-stage methods, 301

Unscaled criteria, 133

Volumes of distribution, 389

Welch's test, 649

Xenobiotics, 491